Catalyst Dossier · compiled by CeliA 🧫

Atea Pharmaceuticals, Inc. (AVIR)

Pharmaceutical Preparations · market cap $349M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10
2026-09-15 (est.)Phase 3 · Bemnifosbuvir-Ruzasvir (BEM/RZR)imp 9/10
2026-12-15 (est.)Phase 3 · Bemnifosbuvir-Ruzasvirimp 9/10
2026-12-31Phase 3imp 7/10

Pipeline

Asset	Phase	Indication
Bemnifosbuvir	Phase 2	Chronic Hepatitis C Virus
Bemnifosbuvir (BEM)	Phase 3	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
Bemnifosbuvir-Ruzasvir	Phase 3	HEPATITIS C VIRUS CHRONIC INFECTION
Bemnifosbuvir-Ruzasvir (BEM/RZR)	Phase 3	HEPATITIS C VIRUS CHRONIC INFECTION
AT-527	Phase 2	Hepatitis C

Price & technical context

3-month

-11.2%

6-month

+32.8%

12-month

+32.8%

52-wk range

$2.82–$6.15

vs 50-day MA

+0.4%

vs 200-day MA

+14.9%

Realized vol

49.6%

Max drawdown

-36.6%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AVIR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.